Chapter 5: Guideline Recommendations: Which AAD and for Whom?

Area of Science:

• Cardiology
• Clinical Guidelines
• Pharmacology

Background:

• Atrial fibrillation (AF) management guidelines from AHA/ACC/HRS and ESC provide frameworks for antiarrhythmic drug (AAD) selection.
• AAD choice is influenced by patient factors such as structural heart disease (SHD), coronary artery disease, and heart failure (HF) type.

Purpose of the Study:

• To discuss current guidelines for AF management, focusing on appropriate AAD selection.
• To identify patient populations suitable for AAD treatment and evaluate adherence to guideline-directed care.

Main Methods:

• Review of AHA/ACC/HRS and ESC guidelines for AF management.
• Analysis of data from the AIM-AF survey, a multinational study of AF management practices among cardiologists and electrophysiologists.

Main Results:

• Guideline recommendations for AAD selection are based on safety, considering SHD, CAD, and HF.
• The AIM-AF survey revealed inconsistent application of guideline-directed care, with inappropriate AAD selection and patient targeting observed across various drug classes and patient groups.
• Notable findings include overuse of amiodarone in patients without SHD and inappropriate use of sotalol in patients with HFrEF.

Conclusions:

• There is a significant gap between established guidelines for AF management and actual clinical practice regarding AAD selection.
• Improved adherence to guideline-directed care is necessary to optimize safety and efficacy in antiarrhythmic drug therapy for atrial fibrillation.
• Further education and implementation strategies are needed to ensure appropriate patient selection and drug choice in AF management.